DRKS00020821已完成不适用
Prospective evaluation of ADAMTS-13, von Willebrand factor and Interleukin-6 in vascular surgery - /
Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum0 个研究点目标入组 93 人开始时间: 2020年3月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 93
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. Patient information and written informed consent
- •2. Age of majority (=>18 years)
- •3. patients of the Clinic for Vascular and Endovascular surgery undergoing one of the following procedures: Carotid TEA, Femoral TEA/bypass grafting of the lower extremity, EVAR, open aortic surgery
排除标准
- •1. missing patient information or informed consent
- •2. known TTP in medical history
- •3. current pregnancy
研究者
相似试验
Unknown
不适用
Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)Thrombotic MicroangiopathiesNCT02373267University of Cologne100
已完成
2 期
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)Acquired Thrombotic Thrombocytopenic Purpura (aTTP)NCT03922308Shire28
未知
3 期
DS-7113b phase III studyModerate to severe cancer painJPRN-jRCT2080222239DAIICHISANKYO Co.,Ltd.
进行中（未招募）
3 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, without Inhibitory Antibodies to Factor VIII or IXCTRI/2018/07/014698Sanofi Genzyme
已完成
1 期
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102GlioblastomaNCT03636477Alaunos Therapeutics21